Trials / Completed
CompletedNCT04487067
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Atezolizumab 1200 mg IV infusion q3w |
| DRUG | Bevacizumab | Bevacizumab 15 mg/kg IV Q3W |
Timeline
- Start date
- 2020-08-25
- Primary completion
- 2024-08-13
- Completion
- 2024-08-13
- First posted
- 2020-07-27
- Last updated
- 2025-09-22
- Results posted
- 2025-09-22
Locations
21 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04487067. Inclusion in this directory is not an endorsement.